Gilead Sciences EPS - Earnings per Share 2010-2022 | GILD

Gilead Sciences annual and quarterly earnings per share history from 2010 to 2022. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Gilead Sciences EPS for the quarter ending March 31, 2022 was $0.02, a 98.54% decline year-over-year.
  • Gilead Sciences EPS for the twelve months ending March 31, 2022 was $3.58, a 1332% increase year-over-year.
  • Gilead Sciences 2021 annual EPS was $4.93, a 4830% increase from 2020.
  • Gilead Sciences 2020 annual EPS was $0.1, a 97.63% decline from 2019.
  • Gilead Sciences 2019 annual EPS was $4.22, a 1.2% increase from 2018.
Gilead Sciences Annual EPS
2021 $4.93
2020 $0.10
2019 $4.22
2018 $4.17
2017 $3.51
2016 $9.94
2015 $11.91
2014 $7.35
2013 $1.81
2012 $1.64
2011 $1.77
2010 $1.66
2009 $1.41
Gilead Sciences Quarterly EPS
2022-03-31 $0.02
2021-12-31 $0.30
2021-09-30 $2.05
2021-06-30 $1.21
2021-03-31 $1.37
2020-12-31 $1.25
2020-09-30 $0.29
2020-06-30 $-2.66
2020-03-31 $1.22
2019-12-31 $2.13
2019-09-30 $-0.92
2019-06-30 $1.47
2019-03-31 $1.54
2018-12-31 $0.01
2018-09-30 $1.60
2018-06-30 $1.39
2018-03-31 $1.17
2017-12-31 $-2.93
2017-09-30 $2.06
2017-06-30 $2.33
2017-03-31 $2.05
2016-12-31 $2.34
2016-09-30 $2.49
2016-06-30 $2.58
2016-03-31 $2.53
2015-12-31 $3.17
2015-09-30 $3.06
2015-06-30 $2.92
2015-03-31 $2.76
2014-12-31 $2.15
2014-09-30 $1.67
2014-06-30 $2.20
2014-03-31 $1.33
2013-12-31 $0.45
2013-09-30 $0.47
2013-06-30 $0.46
2013-03-31 $0.43
2012-12-31 $0.47
2012-09-30 $0.43
2012-06-30 $0.46
2012-03-31 $0.28
2011-12-31 $0.43
2011-09-30 $0.48
2011-06-30 $0.47
2011-03-31 $0.40
2010-12-31 $0.39
2010-09-30 $0.42
2010-06-30 $0.40
2010-03-31 $0.46
2009-12-31 $0.43
2009-09-30 $0.36
2009-06-30 $0.31
2009-03-31 $0.32
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $79.360B $27.305B
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00